Form 4: Processa Pharmaceuticals Executive Lin Reports Stock Transactions After Reverse Stock Split

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports stock transactions including the distribution of vested restricted shares and adjustments due to a 20-to-1 reverse stock split.

Summary

• Patrick Lin, Chief Business Strategy Officer at Processa Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The transactions include the distribution of 1,675 vested restricted shares on January 1, 2024.
• A subsequent transaction on the same date involved the disposition of 539 shares at a price of $2.79.
• The filing reflects adjustments due to a 20-to-1 reverse stock split that took effect on January 22, 2024.
• Following these transactions, Lin directly owns 28,614 shares of common stock and 20,132 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about insider transactions and the impact of the reverse stock split.

Key Dates

Keywords

Form 4, Processa Pharmaceuticals, Stock Transactions, Reverse Stock Split, Beneficial Ownership, Patrick Lin, Restricted Stock Units